Maternal variants in NLRP and other maternal effect proteins are associated with multilocus imprinting disturbance in offspring by Begemann, Matthias et al.
                          Begemann, M., Rezwan, F. I., Beygo, J., Docherty, L. E., Kolarova, J.,
Schroeder, C., ... Mackay, D. J. G. (2018). Maternal variants in NLRP and
other maternal effect proteins are associated with multilocus imprinting
disturbance in offspring. Journal of Medical Genetics, 55(7), 497-504.
https://doi.org/10.1136/jmedgenet-2017-105190
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/jmedgenet-2017-105190
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Begemann M, et al. J Med Genet 2018;0:1–8. doi:10.1136/jmedgenet-2017-105190
Original article
Maternal variants in NLRP and other maternal effect 
proteins are associated with multilocus imprinting 
disturbance in offspring
Matthias Begemann,1 Faisal i rezwan,2 Jasmin Beygo,3 louise e Docherty,4 
Julia Kolarova,5 christopher Schroeder,3 Karin Buiting,3 Kamal chokkalingam,6 
Franziska Degenhardt,7 emma l Wakeling,8 Stephanie Kleinle,9 
Daniela gonzález Fassrainer,9 Barbara Oehl-Jaschkowitz,10 claire l S turner,11 
Michal Patalan,12 Maria gizewska,12 gerhard Binder,13 can thi Bich ngoc,14 
Vu chi Dung,14 Sarju g Mehta,15 gareth Baynam,16,17 Julian P Hamilton-Shield,18 
Sara aljareh,2 Oluwakemi lokulo-Sodipe,2,19 rachel Horton,2,19 reiner Siebert,5 
Miriam elbracht,1 isabel Karen temple,2,19 thomas eggermann,1 Deborah J g Mackay2
Epigenetics
To cite: Begemann M, 
rezwan Fi, Beygo J, et al. 
J Med Genet epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
jmedgenet-2017-105190
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
jmedgenet- 2017- 105190).
For numbered affiliations see 
end of article.
Correspondence to
Dr Deborah J g Mackay, Faculty 
of Medicine, University of 
Southampton, Southampton 
SP2 8BJ, UK;  djgm@ soton. ac. uk
received 1 December 2017
revised 16 January 2018
accepted 15 February 2018
AbsTrACT
background genomic imprinting results from 
the resistance of germline epigenetic marks to 
reprogramming in the early embryo for a small 
number of mammalian genes. genetic, epigenetic or 
environmental insults that prevent imprints from evading 
reprogramming may result in imprinting disorders, which 
impact growth, development, behaviour and metabolism. 
We aimed to identify genetic defects causing imprinting 
disorders by whole-exome sequencing in families with 
one or more members affected by multilocus imprinting 
disturbance.
Methods Whole-exome sequencing was performed in 
38 pedigrees where probands had multilocus imprinting 
disturbance, in five of whom maternal variants in NLRP5 
have previously been found.
results We now report 15 further pedigrees in which 
offspring had disturbance of imprinting, while their 
mothers had rare, predicted-deleterious variants in 
maternal effect genes, including NLRP2, NLRP7 and 
PADI6. as well as clinical features of well-recognised 
imprinting disorders, some offspring had additional 
features including developmental delay, behavioural 
problems and discordant monozygotic twinning, while 
some mothers had reproductive problems including 
pregnancy loss.
Conclusion the identification of 20 putative maternal 
effect variants in 38 families affected by multilocus 
imprinting disorders adds to the evidence that maternal 
genetic factors affect oocyte fitness and thus offspring 
development. testing for maternal-effect genetic variants 
should be considered in families affected by atypical 
imprinting disorders.
InTroduCTIon
Imprinting disorders are caused by genetic 
and epigenetic variations altering the effective 
gene dosage of imprinted genes, whose expres-
sion is normally restricted by parent of origin.1 
They include among others the overgrowth 
disorder Beckwith-Wiedemann syndrome (BWS; 
overgrowth, macroglossia, exomphalos, hemihy-
pertrophy and predisposition to Wilms tumour), 
the growth restriction disorders Silver-Russell 
syndrome (SRS; restricted growth, asymmetry and 
poor feeding) and Temple syndrome (TS; growth 
restriction, poor feeding, early puberty and obesity) 
and transient neonatal diabetes mellitus (TNDM; 
low birth weight, macroglossia and recurrence of 
diabetes).
A subset of patients with imprinting disorder 
show multilocus imprinting disturbance (MLID), 
that is, DNA methylation disturbance of multiple 
imprinted genes across the genome, with different 
imprinting disturbances seen in different patients.2 3 
Clinically, MLID is generally reported to be associ-
ated with a presentation of a ‘classical’ imprinting 
disorder; for example, ~30% of patients with BWS 
and hypomethylation of KCNQ1OT1 TSS DMR 
(KCNQ1OT1 transcriptional start site differentially 
methylated region) are shown to have MLID and 
~30% of SRS patients with hypomethylation of 
H19 TSS DMR. However, clinically heterogeneous 
features may affect growth, development, metabo-
lism and behaviour, and some studies have shown 
an excess of additional clinical anomalies. In most 
MLID cases, no genetic cause has been found, but 
some cases are associated with assisted reproduc-
tive technology (ART) or with genetic variations 
in genes expressed during very early embryonic 
development.4–8
During the early embryonic period, there is 
comprehensive epigenetic reprogramming of sperm 
and oocyte genomes, zygotic genome activation 
(ZGA) and onset of differentiation.9 10 Before full 
ZGA (at the eight-cell and two-cell stages in humans 
and mice, respectively), the early embryo is tran-
scriptionally silent and uses maternally provided 
transcripts and proteins synthesised abundantly in 
the growing oocyte during its maturation. Genes 
of maternal origin with early embryonic expression 
are said to have ‘maternal effect’, and inactivation 
of maternal effect genes in mice causes impaired 
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or delayed preimplantation development, frequently leading to 
embryo demise.
A group of maternally encoded factors, including NLRP5 
(Mater), TLE6, OOEP (Moep), KHDC3L (Filia) and PADI6, 
are among the most highly expressed proteins in both mouse 
and human oocytes.11 12 In mouse, they form a large complex 
referred to as the subcortical maternal complex (SCMC), which 
is essential for preimplantation development.13 A similar SCMC 
including KHDC3L, NLRP5, OOEP and TLE6 has been identi-
fied in human cleavage-stage embryos.14
In humans, maternal effect mutations of NLR family, pyrin 
domain-containing 5 (NLRP5) are associated with heteroge-
neous outcomes in offspring, including MLID in liveborn chil-
dren and pregnancy losses and infertility in mothers.7 The NLRP 
protein family includes two other known maternal effect genes: 
NLRP7 and NLRP2. NLRP7 mutations are the major known 
cause of biparental hydatidiform mole (BiHM), a non-viable 
reproductive outcome associated with absence of fetal develop-
ment, abnormal trophoblastic development and complete pater-
nalisation of maternal imprinting,15 but NLRP7 mutations were 
also described in families with MLID.6 8 Maternal mutation of 
NLRP2 was found in a family with MLID.5 KHDC3L maternal 
mutations are a rare cause of familial BiHM.16 Mutations of 
PADI6 and TLE6 were described in mothers undergoing in vitro 
fertilisation for infertility, whose embryos arrested at the two-cell 
stage,17 18 although imprinting was not analysed in these cases.
Neither human subjects nor murine models are ideal for 
study of maternal effect genes because, on the one hand, mouse 
genetics and development do not fully mirror the human situ-
ation, and on the other hand, human studies of early develop-
ment are ethically and technically challenging. Therefore, there 
is a need to describe human genetic, epigenetic and clinical 
findings in MLID to inform both clinical diagnosis and murine 
modelling. Here we present data from an international cohort of 
families with MLID, where whole-exome sequencing (WES) has 
identified rare variants in mothers associated with imprinting 
disorders and other adverse outcomes in offspring.
METhods
study cohort and ethics
Probands were initially referred with a clinical suspicion of an 
ID and were eligible for research recruitment if initial diagnostic 
testing of blood-derived DNA revealed methylation disturbance at 
any imprinted locus. If subsequent testing revealed MLID, further 
research-based investigation was undertaken, including WES anal-
ysis. Thirty-eight such families were included in this study. It should 
be noted that MLID was not associated with parental unidiploidy 
(genomewide uniparental disomy) in any case.
Families 1–3, 6 and 11–12 were recruited by the German coop-
eration partners in the course of the German ‘Imprinting Network’, 
and the study was approved by the ethical committee at the Univer-
sity Hospital Aachen (EK-302-16). Families 4–5, 7–10 and 13–15 
were consented into the study ‘Imprinting disorders – finding out 
why’ (IDFOW: Southampton and South West Hampshire Research 
Ethics approval 07/H0502/85) through the UK Comprehensive 
Local Research network (h ttp s:/ /www.southampton.a c.uk/genet-
icimprinti ng/i nfor mati onpa tients/ imprinting findingoutwhy. page, 
accessed October 2017), selected from approximately 1200 indi-
viduals recruited from the UK, Europe, Asia, Australia and the USA 
by virtue of detection of MLID and availability of maternal DNA. 
Further clinical information on families 5 and 8 was obtained 
through recruitment into the ‘Study of Adults and Adolescents with 
Russell-Silver Syndrome in the UK’ (STAARS UK; https://www. 
southampton. ac. uk/ geneticimprinting/ informationpatients/ staars. 
page, accessed October 2017).
DNA from a total of 38 families was analysed by WES: 13 
from the German consortium and 25 from the UK cohort. In one 
German and four UK families, maternal NLRP5 variants were 
previously reported.7 In some family members, insufficient DNA 
was available for WES; confirmation of variants in these families 
was performed by Sanger sequencing.
Exome sequencing
For German pedigrees, Nextera Rapid Capture Exome 
(FC-140–1083, Illumina, California, USA) was used according 
to the manufacturer’s protocols. Libraries were sequenced on 
a NextSeq500 platform with 2×151 paired-end reads and 
NextSeq high output V.2 chemistry. FASTQ files were generated 
using the standard Illumina pipeline (V.1.0.0). Paired-end exome 
sequence reads were aligned to the hg38 human reference 
genome using Burrows-Wheeler Aligner (BWA-MEM V.0.7.12) 
to produce binary sequence alignment format (BAM) files, 
and samblaster (V.0.1.24) was used to remove duplicate reads. 
Sambamba (V.0.6.6) was applied to sort and index the alignment 
and Freebayes (V.0.9.21) to determine single-nucleotide variants 
including SNPs and indel (insertion–deletion) alleles and predict 
and genotype variants for each sample. Raw variant calls were 
outputted in variant call format file, and variant filtration was 
performed for both SNPs and indels to remove low quality and 
potentially false-positive variants. Variant data were annotated 
using SnpEff (V.4.2). UK pedigrees were sequenced with the 
Agilent SureSelect V.5 exome capture kit encompassing 51 Mb 
of genome sequence (Santa Clara, USA). Paired-end exome 
sequence reads were aligned to HGRC19 using BWA-MEM 
(V.0.7.5a), and duplicate reads were removed with Picard 
(V.1.95). GATK (V.3.0–0)(51) was used to realign and recalibrate 
BAM files and to predict and genotype variants for each sample. 
VCF files were annotated using Annovar (V.2013 Aug23) and 
KggSeq (V.0.6). Sanger sequencing confirmed exome variants 
and established their inheritance.
In silico prediction of variant pathogenicity and significance.
The pathogenicity of the variants identified was predicted using 
the online tools Variant Effect Predictor (http://www. ensembl. 
org/ Tools/ VEP) and PROVEAN (http:// provean. jcvi. org/ 
genome_ submit_ 2. php? species= human, accessed July 2017), 
both applied with standard procedures and settings. Patho-
genicity predictions are summarised in Results and detailed in 
online supplementary table 1.
Hypergeometric analysis was used to estimate the statistical 
significance of the number of variants found in patients. For 
each gene in which variants were identified, the number of 
maternal variants with minor allele frequency (MAF) <0.001 
was determined, as well as the cumulative frequency of variants 
with MAF <0.001 in ExAc-ALL (http:// exac. broadinstitute. org, 
accessed October 2017). The statistical hypergeometric distribu-
tion, given as a p value and false discovery rate (FDR) corrected, 
estimated the likelihood that the number of rare variants (MAF 
<0.001) identified in patients would be found by chance in the 
same number of individuals selected at random from ExAc-ALL; 
for comparison, the hypergeometric p value (FDR corrected) for 
NLRP5 was 0.003.
Epigenetic and epigenomic analysis
Epigenetic analysis was performed by targeted methylation-spe-
cific PCR as previously described19 or by methylation-specific 
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multiplex ligation probe-dependent amplification assay (ME30, 
ME032 and ME034; MRC Holland, Amsterdam, The Neth-
erlands). The loci examined included: DIRAS3 TSS DMR 
(chr1p31.3); PLAGL1 TSS alt-DMR (chr6q24); IGF2R Int2 
DMR (chr6q25); GRB10 alt-TSS DMR (chr7p12); MEST alt-TSS 
DMR (chr 7q32); H19 TSS DMR (chr11p15.5); KCNQ1OT1 
TSS DMR (chr11p15.5); MEG3 TSS DMR (chr14q32); SNURF 
TSS DMR (chr15q11.2); IGF1R Int2 DMR (chr15q26); PEG3 
TSS DMR (chr19q13); GNAS-AS1 TSS DMR (chr20q13.32); 
and GNAS A/B TSS DMR (chr20q13.32).
rEsulTs
Coding variants of NLRP2 were identified in five mothers, of NLRP7 
in three mothers, of PADI6 in four mothers and of OOEP, UHRF1 
and ZAR1 in one mother each of offspring with MLID. Despite the 
overall scarcity of MLID, mothers harboured a statistically signifi-
cant excess of such variants in NLRP2, NLRP7 and PADI6. Table 1 
summarises the genetic variants in mothers, the clinical presenta-
tions of the offspring and the loci at which imprinting disturbances 
were detected by targeted testing. Further clinical details are given 
in online supplementary information, while genetic and epigenetic 
Table 1 Summary of clinical, genetic and epigenetic features in families with maternal effect variants 
Family Gene Maternal effect variant* hypomethylated loci†
Maternal reproductive 
history of note Family history of note
Clinical features of note in 
proband
Mutation 
previously 
reported
Family previously 
reported: ref 
(patient)
1 NLRP2 NM_017852.4:c.
[1479_1480del];[1479_1480del], 
p.[(Arg493SerfsTer32)];[(Arg493SerfsTer32)]
M hom; P1 het; P2 het
PLAGL1, GRB10, MEST, 
KCNQ1OT1, GNAS
Two children affected 
by MLID, one early 
abortion (gw 8), two late 
miscarriages (gw 24 and gw 
36), one healthy child
Mother of proband has 
one healthy sister with 
three healthy sons
Son: omphalocele, macroglossia, 
neonatal hypoglycaemia, 
heart defect, developmental 
delay. Daughter: macroglossia, 
dysmorphisms, prominent eyes, 
developmental delay.
4
2 NLRP2 NM_017852.4:c.[2237del];[=], 
p.[(Asn746ThrfsTer4)];[=]
M, P het
KCNQ1OT1, H19, MEST In vitro Fertilisation, triplet, 
not monozygotic
NR SRS (NH-CSS: 6/6) 20 (patient 2)
3 (patient 31)
3 NLRP2 NM_017852.4:c.[2860_2861del];[=], 
p.[(Cys954GlnfsTer18)];[=]
M het
GRB10, MEST, 
H19, KCNQ1OT1, 
MEG3,GNAS-AS, GNAS
NR, only child Sister with three 
abortions, no live births
BW at 27 wg 465 g, OFC 32 cm. 
PNGR, respiratory support for 
2 months, gastric tube feeding 
for first year. Microcephaly, 
precocious puberty, dysmorphism. 
Developmental delay. 47,XXY
4 NLRP2 NM_017852.4:c.[314C>T];[=], 
p.[(Pro105Leu);[=]
M het
PLAGL1, MEST, DIRAS3, 
IGF1R, IGF2R
One further child, at least 
two miscarriages.
Sibling of proband has 
anxiety disorder
BW 9th centile, neonatal 
hyperglycaemia, remission at 
3 months, childhood height and 
weight >99th centile, autistic 
spectrum disorder, speech and 
language delay
5 NLRP2 NM_017852.4:c.[1885T>C(;)2401G>A], 
p.[(Ser629Pro)(;)(Ala801Thr)]
M, P het both variants
H19, IGF2R One subsequent healthy 
child, one miscarriage
NR SRS: NH-CSS 4/6; also bilateral radial 
anomalies, abnormalities of thumbs, 
single kidney
19
6 NLRP7 NM_001127255.1:c.[2161C>T];[2573T>C]; 
NP_001120727.1:p.[(Arg721Trp)];[(Ile858Thr)]
M het both variants; P not tested
GRB10, MEST, 
KCNQ1OT1
Two early abortions (gw 4 
and gw 4)
1 induced abortion (gw 19)
Sister of proband's 
mother was also 
compound heterozygous; 
one healthy child (born 
at gw 26), three early 
abortions (gw 4, gw 
6, gw 7); one ongoing 
pregnancy, ultrasound  
normal, no MLID, 
p.(Ile858Thr)
Induced abortion at 19 gw. 
Omphalocele, shortened humeri. 
Mesenchymal placenta.
21,22
7 NLRP7 NM_001127255.1:c.[749T>G];[1104T>G]; 
p.[(Phe250Cys)];[(Ile368Met)] (M compound 
het; (P Ile368Met het)
KCNQ1OT1, PLAGL1, 
IGF2R, MEST, DIRAS3, 
IGF1R
NR NR BW 91st centile, exomphalos, 
macroglossia, neonatal diabetes, 
feeding difficulties in infancy, 
motor/speech delay, duplex kidneys, 
hemihypertrophy, scoliosis
20
8 NLRP7 NM_001127255.1:c.[2156C>T];[=], 
p.[(Ala719Val)];[=] (M het; P het)
H19, IGF1R, IGF2R NR, two additional healthy 
children
NR SRS: NH-CSS 5/6 5, 20
9 PADI6 NM_207421.3:c.[902G>A(;)1298C>T], 
p.[(Arg301Gln)(;)(Pro433Leu)] (M compound 
het; P not tested)
H19, MEG3 NR, only child Maternal grandpaternal 
family history of 
pregnancy loss: one 
healthy child, one with 
low birth weight, four 
stillbirths including a 
twin pair
BW 2nd centile, preserved OFC, 
micrognathia, hypotonia and feeding 
difficulties in infancy. In childhood, 
facial asymmetry, regrognathia, 
broad fleshy nasal tip, height 
10th–25th centile, weight 90th 
centile.
19
10 PADI6 NM_207421.3:c.[1124T>C];[1639G>A], 
p.[Leu375Ser)];[(Asp547Asn)] (M compound 
het; P Asp547Asn het)
KCNQ1OT1, GRB10, H19, 
MEST, IGF2R, IGF1R
NR, only child NR BW 90th–97th centile, macrosomia, 
macroglossia, asymmetry, 
naevus flammeus, ear creases, 
developmental delay
3 (patient 31)
11 PADI6 NM_207421.3:c.[1046A>G];[=], 
p.[(Asp349Gly)];[=] (M het)
H19, IGF2R, GRB10, 
MEST, MEG3, SNRPN, 
GNAS-AS, GNAS
Two healthy children, 
patient born at term
NR Referred for testing as SRS, 
but NH-CSS negative (3/6): no 
relative macrocephaly, no feeding 
difficulties, no protruding forehead; 
developmental delay
12 PADI6 NM_207421.3:c.[433A>G];[=], 
p.[(Lys145Glu)];[=] (M het)
H19, IGF2R, MEG3 NR, only child NR SRS: NH-CSS 4/6: no feeding 
difficulties, no asymmetry
13 OOEP NM_001080507.2:c.[109C>T];[109C>T], 
p.[(Arg37Trp)];[(Arg37Trp)] (M hom, P het)
PLAGL1, IGF2R, DIRAS3, 
GRB10, SNRPN, IGF1R
NR NR BW <0.4th centile. Hyperglycaemia 
1–3.5 months, pelvic renal dilatation, 
developmental delay
14 UHRF1 NM_013282.4:c.[514G>A];[=], 
p.[(Val172Met)];[=] (M het, P het)
H19, PLAGL1, IGF2R, 
KCNQ1OT1, IGF1R, 
PEG3, GNAS-AS
Proband is one of 
discordant monozygotic 
twin pair
NR Discordant monozygotic twin. SRS: 
NH-CSS 5/6; also kidney failure in 
infancy, bilateral renal dysplasia
15 ZAR1 NM_175619.2:c.[130G>T];[=], 
p.[(Glu44Cys)];[=] (M het, P het)
KCNQ1OT1, GNAS, 
DIRAS3, IGF1R
Two healthy siblings, one 
miscarriage
NR BW >98th centile, mild macroglossia, 
consistently high weight (>98th 
centile)
47The table summarises clinical, genetic and epigenetic features in families with maternal-effect variants. gw: gestational week; NR: not reported; BW: birth weight; OFC: occipitofrontal circumference; PNGR: postnatal growth restriction; 
NH-CSS: Netchine-Harbison Clinical Scoring System47 (Netchine-Harbison score from 6 parameters: intrauterine growth restriction, postnatal growth restriction, relative macrocephaly, feeding difficulties, asymmetry, protruding forehead). *M: 
variant detected in mother (by definition); P: variant detected in proband; hom: homozygous; het: heterozygous. 
 †All loci were tested, but the table lists only loci at which hypomethylation was detected. 
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findings are further detailed in online supplementary tables 1 and 
2, respectively. None of the pedigrees reported any family history 
of imprinting disorders or congenital disorders, and none except 
family 1 reported consanguinity. Where pregnancies were achieved 
by ART, this is stated in clinical information and in table 1. All 
pedigrees are of Caucasian ethnicity, except for families 1 and 13, 
of Saudi and Southeast Asian origin, respectively.
NLRP2 
Proband 1 (figure 1A) presented with clinical features of BWS 
and additionally developmental delay and a heart defect. The 
mother had a further child with BWS-MLID and also expe-
rienced three pregnancy losses. In the mother, the NLRP2 
variant p.(Arg493SerfsTer32) was present homozygously. As 
expected, the two affected children were heterozygous. This 
maternal variant was previously reported in a family of Pakistani 
origin where the offspring were affected by MLID.5 Proband 
2 with SRS, as previously reported,20 is one of trizygous trip-
lets resulting from intracytoplasmic sperm injection. He inher-
ited from his mother the heterozygous frameshift mutation 
p.(Asn746ThrfsTer4). Proband 3 presented with 47,XXY karyo-
type, symmetrical growth restriction and developmental delay 
that were not fully consistent with any specific ID diagnosis. 
The mother was heterozygous for the stop-gain variant p.(Cys-
954GlnfsTer18), but the variant was not present in the patient. 
The sister of the mother experienced three pregnancy losses and 
had no liveborn children, but no sample was available to deter-
mine her carrier status for the variant. Proband 4 affected by 
TNDM, and developmental delay is the first of three children. 
One of his siblings has autism; the mother additionally suffered 
at least two pregnancy losses. The mother but not the proband 
had the heterozygous NLRP2 variant p.(Pro105Leu), predicted 
to be possibly deleterious. Proband 5 with SRS shared with 
his mother two variants in NLRP2: p.(Ser606Pro) and p.(Al-
a778Thr), each heterozygous; the former was predicted in silico 
to be deleterious.
NLRP7 
Proband 6 (figure 1B) was a fetus ascertained at 19 weeks of gesta-
tion with dysmorphic features suggestive for BWS (omphalocele 
Figure 1 Pedigrees of selected families affected by multilocus imprinting disorders. (a) Family 1 with two BWS-MliD children, who were additionally 
reported to be developmentally delayed. (B) Family 6 with recurrent pregnancy loss and stillbirths, and one child with MliD and features reminiscent of BWS. 
BWS, Beckwith-Wiedemann syndrome; gw, gestational weeks; MliD, multilocus imprinting disturbance.
 o
n
 19 April 2018 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2017-105190 on 24 March 2018. Downloaded from 
5Begemann M, et al. J Med Genet 2018;0:1–8. doi:10.1136/jmedgenet-2017-105190
Epigenetics
and placental mesenchymal dysplasia) warranting termination; 
the mother had two further early pregnancy losses. The mother 
showed compound heterozygosity for two NLRP7 variants: 
p.(Arg721Trp) and p.(Ile858Thr); the variant p.(Arg721Trp) 
has been reported in families with BiHM and recurrent spon-
taneous abortion, but the latter’s pathogenicity is unclear.21 22 
The sister of mother 6 was also compound heterozygous for 
both variants; she experienced recurrent pregnancy losses but 
also had a healthy son. Sanger sequencing of the mother of the 
two sisters showed the presence of the p.(Arg.721Trp) variant 
only. Proband 7 presented with clinical features of both BWS 
and TNDM. Her mother had two heterozygous missense vari-
ants within the NACHT domain of NLRP7: the novel variant 
p.(Ile368Met) was found only in the mother, but p.(Phe250Cys) 
was detected in both mother and proband. Of note, missense 
mutation of p.(Phe250Cys) is reported in BiHM.23 Proband 8 
had clinical features of SRS. The heterozygous variant NLRP7, 
p.(Ala719Val), identified in the proband and his mother, is 
predicted as tolerated by in silico tools, but the same variant was 
identified in a pedigree affected by MLID6 and in a mother who 
suffered four pregnancy losses.23
PADI6 
Proband 9 was clinically diagnosed in infancy with SRS, but 
features of TS emerged in childhood. Her mother had two hetero-
zygous variants in PADI6: p.(Arg301Gln) and p.(Pro433Leu), 
both predicted to be deleterious. No DNA sample from the 
proband was available to determine inheritance of either 
variant. Proband 10 showed features of BWS. His mother had 
two heterozygous variants in PADI6: p.(Leu375Ser), not inher-
ited by her son and predicted as deleterious, and p.(Asp547Asn), 
predicted as benign and inherited by her son. Proband 11 was 
referred with clinical features reminiscent of SRS. The maternal 
heterozygous variant p.(Asp349Gly) was identified; this was not 
inherited by the child. Proband 12 was ascertained with a clinical 
presentation of SRS; in his mother but not in him, the PADI6 
variant p.(Lys145Glu) was present heterozygously.
OOEP, UHRF1 and ZAR1
Proband 13 had a clinical presentation of TNDM. A missense 
variant in OOEP, p.(Arg37Trp) was present heterozygously in 
proband 13 and his father and homozygously in his mother. 
Proband 14, affected by SRS, was one of discordant monozy-
gotic (DMZ) twins; her cotwin was clinically and epigenetically 
normal. The UHRF1 variant p.(Val172Met), broadly predicted 
as deleterious, was present in the mother and both twins. 
Proband 15 is the third of three children; between the first and 
second children, the mother suffered one pregnancy loss. The 
proband had mild macroglossia and high birth weight, but no 
other features of BWS. She and her mother shared a hetero-
zygous variant in ZAR1: p.(Gly44Cys), predicted as possibly 
deleterious.
dIsCussIon
We present here 15 families, with imprinting disturbance in 
offspring and rare maternal variations in proteins expressed 
abundantly in oocytes and zygotes, and we propose that the 
maternal variants are associated with the epigenetic and clinical 
features of the offspring.
Most probands presented features of classic imprinting disor-
ders, prompting epigenetic diagnosis. However, the majority of 
offspring reported here had additional clinical features, atyp-
ical of their primary diagnoses, including developmental delay, 
autistic features and organ malformations. MLID is inherently 
heterogeneous, aetiologically, epigenetically and phenotypi-
cally.2 Further patients and further analysis will be required to 
determine whether epigenotype:phenotype correlations exist 
to explain these features, but this is challenging because of the 
requirement of testing in specific tissues and at key develop-
mental times to confirm the causal relationship. For example, 
of five probands with hypomethylation of both H19 TSS DMR 
and KCNQ1OT1 TSS DMR, three presented with SRS and one 
with BWS. The clinical presentation of each patient may have 
reflected the most severe methylation disturbance in that patient 
or the pattern of epigenetic disturbances in critical somatic 
tissues for the two disorders.
One proband (pedigree 14) is a DMZ twin. The incidence of 
twinning is elevated in imprinting disorders, particularly BWS; 
the majority are DMZ twins with methylation loss, and MLID 
is also over-represented in these patients.24 25 We previously 
described a proband with MLID who was a DMZ twin, whose 
mother had a variant in NLRP5.7 The addition of this present 
case supports the hypothesis that MZ twinning is connected with 
epigenetic disturbance in early development and, in some cases, 
a genetic predisposition.
Offspring of mothers with maternal effect variants showed 
heterogeneous and mosaic disturbance of both maternal and 
paternal genomic imprints. This epigenetic heterogeneity 
contrasts with the relatively consistent MLID characteristic of 
recessive ZFP57 mutation,4 or the complete loss of maternal 
methylation seen in hydatidiform moles,26 and suggests that 
these variants affect not gametic establishment but postzygotic 
maintenance of imprints. Not all offspring had clinical features 
of imprinting disorders (although epigenetic disturbance might 
be present in untested, clinically unaffected siblings), suggesting 
that the penetrance of the maternal effect was modified by other 
genetic or environmental factors.
In our cohort, analysis of imprinted DNA methylation was 
only possible in accessible, somatic tissues. It is possible that 
maternal effect mutations disturb the whole process of epig-
enomic reprogamming in the embryo and lead to a ‘crisis’ in 
its development. If the embryo survives, ongoing differentia-
tion and development overwrite these epigenetic errors, leaving 
only imprint changes as evidence of the crisis. Indeed, in cases 
where little or no imprinting disturbance is detectable in acces-
sible tissue, the affected individual may go undiagnosed. Model 
animal studies are required to determine whether maternal effect 
mutations impact the embryo epigenome, and how epigenomic 
disturbance correlates with developmental outcomes. It is also 
noteworthy that two probands had genomic alterations: one 
showed 47XXY and one a duplication of chr20. Mouse models 
deficient in the oocyte protein Filia showed increased genomic 
instability.27 While whole-genome analyses were not undertaken 
in all families, it is possible that the stability as well as the repro-
gramming of the genome is compromised by maternal effect 
mutations.
NLRP7 and NLRP2 are among several NLR gene family 
members tandemly located on human chromosome 19. Some 
NLRPs are involved in humoural immunity28; others are 
expressed abundantly and almost exclusively in the oocyte.
Maternal mutations of NLRP7 are associated with 
BiHM.21–23 29 30 Women with inactivating NLRP7 mutations 
normally have no liveborn children, but pregnancies and live 
births have been reported in women with missense or splicing 
mutations, indicating that residual NLRP7 function is compat-
ible with human development.6 8 20NLRP7 has no murine homo-
logue; in the human genome, it is adjacent to NLRP2 and is 
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likely to represent a recent genomic duplication from it.31 Thus, 
human NLRP2 and NLRP7 proteins may divide, or execute 
redundantly, the murine function of NLRP2. Nlrp2 knockdown 
in mouse germinal vesicles gave rise to embryos that arrested 
between the two-cell and eight-cell stage.32 In a murine Nlrp2 
knockout model, females showed atresia of ovarian follicles, 
reduced fertilisation rates, abnormal early embryogenesis, delay 
or failure in blastocyst formation and prenatal or perinatal 
death with a heterogeneous range of growth and developmental 
defects, together with methylation disturbance (both hypometh-
ylation and hypermethylation) at imprinted loci.33 An indepen-
dent Nlrp2-knockout mouse showed a marked decline in female 
fertility with age.34 Taken together, these observations suggest 
that functional deficit of Nlrp2 impacts early embryogenesis, 
leading to a gradation of subviable and nonviable outcomes, 
associated with altered epigenetic reprogramming, and suscep-
tible to environmental modulation, for example, by maternal 
age.
Nlrp2 and Nlrp5 are components of the SCMC in mouse, 
along with Filia (Khdc3l), Moep, Tle6 and Padi6.13 14 35–44 In 
mouse, maternal ablation of SCMC components causes develop-
mental failure of offspring. Ablation of maternal Mater (Nlrp5) 
causes embryonic arrest at the two-cell stage.35 36 Maternal-null 
Filia embryos have defective zygote spindle assembly and 
chromosome alignment, causing delayed mitosis, gross aneu-
ploidy and reduced maternal fertility.27 Maternal-null Moep 
(the murine homologue of OOEP) embryos show cell division 
defects resulting in arrest at the two-cell to four-cell stage.37 Tle6 
is involved in protein kinase A signalling during oocyte matu-
ration.38 Maternal ablation of murine Padi6 leads to disrupted 
zygotic localisation of ribosomal components, loss of stored 
mRNA, reduced transcription and translation and developmental 
arrest at the two-cell to four-cell stage.39 40 In our cohort, we 
found no maternal variants in TLE6 or KHDC3L but four fami-
lies with rare variants in PADI6 and one family with a variant in 
OOEP. Of note, the Southeast Asian ethnicity of pedigree 13 
raises the possibility that the OOEP variant in this family may be 
under-represented in public databases (dbSNP and ExAC) and 
unrelated to Proband 13’s clinical presentation.
Additionally, we found variants in two other maternal effect 
proteins: UHRF1 and ZAR1. Murine Zar1 is expressed in the 
oocyte and required for progression to the two-cell stage.41 Zar1 
binds the 3′ of mRNAs and, in vitro, suppresses their transla-
tion.42 Murine Uhrf1 (Np95) associates with replicating DNA and 
recruits the DNA maintenance methyltransferase Dnmt1, which 
preferentially methylates hemimethylated DNA.43 44Nlrp2-null 
female mice showed altered localisation of Dnmt1 in oocytes 
and preimplantation embryos as well as disturbed DNA meth-
ylation at imprinted loci.33 This observation is consistent with 
reduced function of UHRF1 impairing maintenance methyla-
tion in the early embryo, leading to stochastic and mosaic DNA 
methylation loss which, at imprinted loci, would not be re-estab-
lished later in development.
The small number of families and the heterogeneity of the 
maternal genetic variants and offspring outcomes preclude 
correlations between genotype, epigenotype and phenotype. 
This study identified coding variants, including homozygosity 
and heterozygosity for non-sense and missense mutations. Of 
six families with maternal homozygous/compound heterozygous 
mutations (families 1, 6, 7, 9, 10 and 13), three (families 1, 7 and 
9) had family histories of non-viable reproductive outcomes as 
well as children affected by MLID, suggesting that these families 
have a trend to greater severity of affectedness. In mothers with 
heterozygous variants, affectedness of offspring may be partly 
contingent on environmental factors. In pedigrees where no 
plausible genetic variants were found in mothers or probands, 
other genetic effects may remain to be identified; otherwise, 
MLID may be caused by environmental factors such as maternal 
lifecourse or age, the age of the oocyte preovulation or postovu-
lation,45 46 or ART (though in 20 pedigrees in whom variants 
were not found, ART was reported in only one, and unknown in 
two others; data not shown).
It will be challenging to prove the functional consequences 
of these variants, because most of the genes concerned are 
expressed only in oocyte and early embryo, their expression and 
function may differ between humans and mice and obvious tech-
nical, practical and ethical restrictions limit the analyses that can 
be performed in humans. However, there is strong justification 
for reporting these variants and examining the potential rele-
vance of maternal effect variation for female reproductive health 
and rare disease.
Importantly, current databases of genetic variants are not reli-
able for considering maternal effect variants, as the individuals 
carrying these variants are likely to develop normally; it is their 
offspring or fertility that are affected, and these data are not 
systematically recorded in any international database to date. 
Women in this cohort had pregnancy losses as well as children 
affected by MLID. It is possible that maternal effect variants are 
associated with adverse reproductive outcomes more widely 
than represented in this study, which focuses on mothers with 
liveborn children with MLID. Current clinical genetic practice 
focuses on the proband, and there is little systematic recording 
of reproductive outcomes in mothers. Ascertainment of further 
cases, and more detailed data collection from mothers and wider 
families, is needed to clarify the incidence and impact of maternal 
effect genetic variants in reproductive and offspring health.
We previously identified five individuals within this cohort 
with MLID and maternal variants in NLRP5.7 At that time, 
NLRP5 was the only gene to show rare variants in more than 
two patients. Recruitment of further patients, and advancing 
literature on maternal effect mutations and their developmental 
effects, prompted re-evaluation of our data. We have now iden-
tified 15 further families with putative maternal effect variants 
and offspring affected by MLID; this gives a total of 20 out of 38 
pedigrees in which maternal effect variants potentially contribute 
to offspring MLID.
This report adds to a growing number of papers describing 
maternal effect variants, particularly NLRP gene variants, asso-
ciated with offspring imprinting disturbance.5–8 These observa-
tions show that a proportion of MLID and atypical imprinting 
disorders have an underlying maternal genetic cause, particularly 
those where clinical problems in siblings or a history of repro-
ductive difficulties are also present, and genetic investigation 
and counselling for imprinting disorders should take this into 
account.
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